Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II benfotiamine add-on to donepezil in mild-to-moderate Alzheimer's disease
ChiCTR1800014316Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of benfotiamine in Alzheimer's disease (AD) (3 arms), sponsored by Huashan Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale 11-item. Started Jan 2018; status: recruiting.
02
Drugs
benfotiamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR1800014316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014316.